Hepatitis Monthly

Published by: Kowsar

Manipulation of Regulatory Cells’ Responses to Treatments for Chronic Hepatitis B Virus Infection

Soheil Tavakolpour 1 , Seyed Moayed Alavian 1 , * and Shahnaz Sali 2
Authors Information
1 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqyiatallah University of Medical Sciences, Tehran, IR Iran
2 Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: , 16 (6); e58751
  • Published Online: May 25, 2016
  • Article Type: Research Article
  • Received: March 17, 2016
  • Revised: April 14, 2016
  • Accepted: April 20, 2016
  • DOI: 10.5812/hepatmon.37927

To Cite: Tavakolpour S, Alavian S M, Sali S. Manipulation of Regulatory Cells’ Responses to Treatments for Chronic Hepatitis B Virus Infection, Hepat Mon. Online ahead of Print ;16(6):e58751. doi: 10.5812/hepatmon.37927.

Abstract
Copyright: Copyright © 2016, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Footnote
References
  • 1. De Clercq E, Ferir G, Kaptein S, Neyts J. Antiviral treatment of chronic hepatitis B virus (HBV) infections. Viruses. 2010; 2(6): 1279-305[DOI][PubMed]
  • 2. Nguyen MH, Keeffe EB. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat. 2009; 16(3): 149-55[DOI][PubMed]
  • 3. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol. 2003; 77(1): 68-76[PubMed]
  • 4. Xue-Song L, Cheng-Zhong L, Ying Z, Mo-Bin W. Changes of Treg and Th17 cells balance in the development of acute and chronic hepatitis B virus infection. BMC Gastroenterol. 2012; 12: 43[DOI][PubMed]
  • 5. Cai D, Mills C, Yu W, Yan R, Aldrich CE, Saputelli JR, et al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother. 2012; 56(8): 4277-88[DOI][PubMed]
  • 6. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014; 343(6176): 1221-8[DOI][PubMed]
  • 7. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest. 2012; 122(2): 529-37[DOI][PubMed]
  • 8. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut. 2012; 61(12): 1754-64[DOI][PubMed]
  • 9. Tavakolpour S. Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus. Dermatol Ther. 2016; [DOI][PubMed]
  • 10. Tavakolpour S, Tavakolpour V. Interleukin 4 inhibition as a potential therapeutic in pemphigus. Cytokine. 2016; 77: 189-95[DOI][PubMed]
  • 11. Tavakolpour S. Interleukin 21 as a new possible player in pemphigus: Is it a suitable target? Int Immunopharmacol. 2016; 34: 139-45[DOI][PubMed]
  • 12. Jiang Y, Ma Z, Xin G, Yan H, Li W, Xu H, et al. Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. Mediators Inflamm. 2010; 2010: 143026[DOI][PubMed]
  • 13. Tavakolpour S. Inhibition of regulatory cells as a possible cure of chronically hepatitis B virus infected patients. Immunol Lett. 2016; 171: 70-1[DOI][PubMed]
  • 14. Wang Q, Zhou J, Zhang B, Tian Z, Tang J, Zheng Y, et al. Hepatitis B virus induces IL-23 production in antigen presenting cells and causes liver damage via the IL-23/IL-17 axis. PLoS Pathog. 2013; 9(6): 1003410[DOI][PubMed]
  • 15. Kamimura D, Bevan MJ. Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo. J Exp Med. 2007; 204(8): 1803-12[DOI][PubMed]
  • 16. Isogawa M, Chung J, Murata Y, Kakimi K, Chisari FV. CD40 activation rescues antiviral CD8(+) T cells from PD-1-mediated exhaustion. PLoS Pathog. 2013; 9(7): 1003490[DOI][PubMed]
  • 17. Li X, Kong H, Tian L, Zhu Q, Wang Y, Dong Y, et al. Changes of costimulatory molecule CD28 on circulating CD8+ T cells correlate with disease pathogenesis of chronic hepatitis B. Biomed Res Int. 2014; 2014: 423181[DOI][PubMed]
  • 18. Blackburn SD, Wherry EJ. IL-10, T cell exhaustion and viral persistence. Trends Microbiol. 2007; 15(4): 143-6[DOI][PubMed]
  • 19. Xiang XG, Xie Q. IL-35: a potential therapeutic target for controlling hepatitis B virus infection. J Dig Dis. 2015; 16(1): 1-6[DOI][PubMed]
  • 20. Khorramdelazad H, Hassanshahi G, Nasiri Ahmadabadi B, Kazemi Arababadi M. High Serum Levels of TGF-beta in Iranians With Chronic HBV Infection. Hepat Mon. 2012; 12(11): 7581[DOI][PubMed]
  • 21. Karimi-Googheri M, Daneshvar H, Nosratabadi R, Zare-Bidaki M, Hassanshahi G, Ebrahim M, et al. Important roles played by TGF-beta in hepatitis B infection. J Med Virol. 2014; 86(1): 102-8[DOI][PubMed]
  • 22. Ye B, Liu X, Li X, Kong H, Tian L, Chen Y. T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis. 2015; 6: 1694[DOI][PubMed]
  • 23. Motavaf M, Safari S, Alavian SM. Interleukin 18 gene promoter polymorphisms and susceptibility to chronic hepatitis B infection: a review study. Hepat Mon. 2014; 14(7): 19879[DOI][PubMed]
  • 24. Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris). 2010; 58(4): 258-66[DOI][PubMed]
  • 25. Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A, et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut. 2009; 58(7): 974-82[DOI][PubMed]
  • 26. Phillips S, Chokshi S, Riva A, Evans A, Williams R, Naoumov NV. CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol. 2010; 184(1): 287-95[DOI][PubMed]
  • 27. Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology. 2005; 41(4): 771-8[DOI][PubMed]
  • 28. Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, King A, et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology. 2000; 32(5): 1117-24[DOI][PubMed]
  • 29. Peng G, Li S, Wu W, Sun Z, Chen Y, Chen Z. Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology. 2008; 123(1): 57-65[DOI][PubMed]
  • 30. Aalaei-Andabili SH, Alavian SM. Regulatory T cells are the most important determinant factor of hepatitis B infection prognosis: a systematic review and meta-analysis. Vaccine. 2012; 30(38): 5595-602[DOI][PubMed]
  • 31. Park Y, Park Y, Han KH, Kim HS. Serum cytokine levels in patients with chronic hepatitis B according to lamivudine therapy. J Clin Lab Anal. 2011; 25(6): 414-21[DOI][PubMed]
  • 32. Zhou Y, Zhang H, Li Y. IL-35 expression in peripheral blood CD4(+) T cells from chronic hepatitis B virus-infected patients directly correlates with virus load. Cytokine. 2015; 73(1): 169-75[DOI][PubMed]
  • 33. Tulek N, Saglam SK, Saglam M, Turkyilmaz R, Yildiz M. Soluble interleukin-2 receptor and interleukin-10 levels in patients with chronic hepatitis B infection. Hepatogastroenterology. 2000; 47(33): 828-31[PubMed]
  • 34. Zhang F, Yao S, Zhang M, Yuan J, Chen X, Zhou B. Roles of circulating soluble interleukin (IL)-6 receptor and IL-6 receptor expression on CD4+ T cells in patients with chronic hepatitis B. Int J Infect Dis. 2011; 15(4): 267-71[DOI][PubMed]
  • 35. Du WJ, Zhen JH, Zeng ZQ, Zheng ZM, Xu Y, Qin LY, et al. Expression of interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection. Diagn Pathol. 2013; 8: 40[DOI][PubMed]
  • 36. Marchant A, Goldman M. T cell-mediated immune responses in human newborns: ready to learn? Clin Exp Immunol. 2005; 141(1): 10-8[DOI][PubMed]
  • 37. Shrivastava S, TrehanPati N, Patra S, Kottilil S, Pande C, Trivedi SS, et al. Increased regulatory T cells and impaired functions of circulating CD8 T lymphocytes is associated with viral persistence in Hepatitis B virus-positive newborns. J Viral Hepat. 2013; 20(8): 582-91[DOI][PubMed]
  • 38. Gong Y, Zhao C, Zhao P, Wang M, Zhou G, Han F, et al. Role of IL-10-Producing Regulatory B Cells in Chronic Hepatitis B Virus Infection. Dig Dis Sci. 2015; 60(5): 1308-14[DOI][PubMed]
  • 39. Das A, Ellis G, Pallant C, Lopes AR, Khanna P, Peppa D, et al. IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol. 2012; 189(8): 3925-35[DOI][PubMed]
  • 40. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 2010; 11(12): 1093-101[DOI][PubMed]
  • 41. Shen P, Roch T, Lampropoulou V, O'Connor RA, Stervbo U, Hilgenberg E, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014; 507(7492): 366-70[DOI][PubMed]
  • 42. Strauss L, Bergmann C, Whiteside TL. IL-15 administration to human CD4+ T cells leads to expansion of CD4+ CD25-cells but to a decrease of CD4+ CD25highFoxp3+ T cells via apoptosis. J Immunol. 2007; 178: 147
  • 43. Lu J, Giuntoli RL, Omiya R, Kobayashi H, Kennedy R, Celis E. Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin Cancer Res. 2002; 8(12): 3877-84[PubMed]
  • 44. Chen YM, Ting CC, Peng JW, Yang WK, Yang KY, Tsai CM, et al. Restoration of cytotoxic T lymphocyte function in malignant pleural effusion: interleukin-15 vs. interleukin-2. J Interferon Cytokine Res. 2000; 20(1): 31-9[DOI][PubMed]
  • 45. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 2013; 13: 5[PubMed]
  • 46. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist. 2008; 13 Suppl 4: 2-9[DOI][PubMed]
  • 47. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4): 252-64[DOI][PubMed]
  • 48. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11(11): 3887-95[PubMed]
  • 49. Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol. 2008; 45(4): 963-70[DOI][PubMed]
  • 50. Evans A, Riva A, Cooksley H, Phillips S, Puranik S, Nathwani A, et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion. Hepatology. 2008; 48(3): 759-69[DOI][PubMed]
  • 51. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology. 2010; 138(2): 682-93[DOI][PubMed]
  • 52. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008; 205(12): 2763-79[DOI][PubMed]
  • 53. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010; 207(10): 2175-86[DOI][PubMed]
  • 54. Liu Y, Gao LF, Liang XH, Ma CH. Role of Tim-3 in hepatitis B virus infection: An overview. World J Gastroenterol. 2016; 22(7): 2294-303[DOI][PubMed]
  • 55. Ju Y, Hou N, Zhang XN, Zhao D, Liu Y, Wang JJ, et al. Blockade of Tim-3 pathway ameliorates interferon-gamma production from hepatic CD8+ T cells in a mouse model of hepatitis B virus infection. Cell Mol Immunol. 2009; 6(1): 35-43[DOI][PubMed]
  • 56. Wu W, Shi Y, Li S, Zhang Y, Liu Y, Wu Y, et al. Blockade of Tim-3 signaling restores the virus-specific CD8(+) T-cell response in patients with chronic hepatitis B. Eur J Immunol. 2012; 42(5): 1180-91[DOI][PubMed]
  • 57. Tavakolpour S. Anti-interleukin and associated receptors monoclonal antibodies therapy in autoimmune diseases. Receptors Clin Investig. 2016; 3(1): 1173
  • 58. Tavakolpour S. The new insight into management of hepatitis B virus patients with flare. Immunol Lett. 2016; [DOI][PubMed]
  • 59. Tavakolpour S, Alavian SM, Sali S. Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review. Hepat Mon. 2016; 16(4)
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader